Rituximab is contraindicated in patients with:
Hypersensitivity to the active substance or to murine proteins, or to any of the excipients.
Active, severe infections.
Patients in a severely immunocompromised state.
Patients who have or had Progressive Multifocal Leukoencephalopathy (PML).
Patients with severe heart failure (NYHA Class IV) or severe uncontrolled cardiac disease.